Comparative Pharmacology
Head-to-head clinical analysis: PRISMASOL BGK 4 2 5 IN PLASTIC CONTAINER versus PRISMASOL BK 0 0 IN PLASTIC CONTAINER.
Peer-Reviewed Evidence
Head-to-head clinical analysis: PRISMASOL BGK 4 2 5 IN PLASTIC CONTAINER versus PRISMASOL BK 0 0 IN PLASTIC CONTAINER.
PRISMASOL BGK 4/2.5 IN PLASTIC CONTAINER vs PRISMASOL BK 0/0 IN PLASTIC CONTAINER
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Prismasol BGK 4/2.5 is a hemofiltration solution used in continuous renal replacement therapy (CRRT). It provides electrolytes and buffer to correct metabolic acidosis and maintain acid-base and electrolyte balance during hemofiltration. The solution contains lactate as a buffer, which is metabolized to bicarbonate in the liver, helping to replace lost bicarbonate and correct metabolic acidosis.
Prismasol BK 0/0 is a sterile, nonpyrogenic bicarbonate-buffered replacement solution for continuous renal replacement therapy (CRRT). It acts as an electrolyte and buffer replacement to correct acid-base disturbances and maintain fluid balance during hemofiltration, with no pharmacologic active drug component.
Continuous renal replacement therapy (CRRT) solution; dose is operator-dependent based on prescribed effluent rate (typically 20-35 mL/kg/h) and patient metabolic needs. Not intended for direct intravenous infusion as a standalone drug.
Administered as a continuous infusion at rates typically between 1000-4000 mL/hour depending on the desired effluent flow rate, patient fluid balance, and metabolic requirements. The solution is used as dialysate (hemodiafiltration) or replacement fluid (hemofiltration). Must be prescribed and administered under physician supervision using intravenous infusion via a dialyzer or hemofilter.
None Documented
None Documented
The components of PRISMASOL BGK 4/2.5 have elimination half-lives that depend on dialysis settings. For electrolytes, the serum half-life following a single dose is approximately 1-2 hours during continuous renal replacement therapy (CRRT) due to continuous removal. Without dialysis, the half-life of potassium is 7-10 hours in renal impairment, but the solution is only used during CRRT, so the effective half-life is governed by dialysis clearance.
Not applicable; PRISMASOL is a dialysate solution, not a drug with systemic absorption; components are removed by dialysis.
PRISMASOL BGK 4/2.5 is a hemodialysis solution containing electrolytes (sodium, potassium, calcium, magnesium, chloride) and glucose. Its components are not metabolized; electrolytes are excreted renally in proportion to renal function, and glucose is either utilized or excreted renally if hyperglycemic. In continuous renal replacement therapy, the solution is removed via the dialysate/effluent (100% removal by dialysis). Renal excretion of electrolytes and glucose accounts for <5% in anuric patients, but in patients with residual renal function, up to 10-20% may be excreted renally. Overall, >95% is removed by the dialysis circuit.
Renal (80-100% in urine as unabsorbed, not metabolized); minimal biliary/fecal.
Category C
Category C
Dialysis Solution
Dialysis Solution